See what CanVECTOR members are publishing to advance the field of venous thromboembolism
Publications since 2016 that are linked to venous thromboembolism and/or anticoagulant therapy

Publications for Sam Schulman

Updated daily

Back to Member List

#	PubMedId	Deleted	Publication
	39178882	0	Glise Sandblad K, Svensson CJ, Svennerholm K, et al. Time trends and excess mortality compared to population controls after a first-time pulmonary embolism or deep vein thrombosis. Thromb Haemost. 2024 Aug 23. doi: 10.1055/a-2402-6192.
	39174231	0	Schulman S, Resnick HE. "2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19": reply. J Thromb Haemost. 2024 Sep;22(9):2672-2673. doi: 10.1016/j.jtha.2024.06.009.
	38733980	0	Schulman S. Recent Advances in Thrombosis and Hemostasis-Part X. Semin Thromb Hemost. 2024 May 11. doi: 10.1055/s-0044-1786753.
	38503600	0	Schulman S, Arnold DM, Bradbury CA, et al. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2024 Mar 18:S1538-7836(24)00113-2. doi: 10.1016/j.jtha.2024.02.011.
	38316416	0	Harenberg J, Gosselin RC, Cuker A, et al. Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper. Thromb Haemost. 2024 Aug;124(8):770-777. doi: 10.1055/a-2261-1811. Epub 2024 Feb 5.
	38158198	0	Johansson I, Benz AP, Kovalova T, et al. Outcomes of Patients with a Mechanical Heart Valve and Poor Anticoagulation Control on Warfarin. Thromb Haemost. 2023 Dec 29. doi: 10.1055/s-0043-1777827.
	37949316	0	Shaw JR, Li N, Abdulrehman J, et al. Periprocedural Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Active Cancer. J Thromb Haemost. 2023 Nov 8:S1538-7836(23)00830-9. doi: 10.1016/j.jtha.2023.10.028.
	37907305	0	Makedonov I, Kahn S, Abdulrehman J, et al. TILE pilot trial study protocol: Tinzaparin Lead-in to Prevent the Post-Thrombotic syndrome study protocol. BMJ Open. 2023 Oct 31;13(10):e064715. doi: 10.1136/bmjopen-2022-064715.
	37739038	0	Lee Cervi A, Applegate D, Stevens SM, et al. Antithrombotic Management of Patients with Deep Vein Thrombosis and Venous Stents: An International Registry. J Thromb Haemost. 2023 Sep 20:S1538-7836(23)00707-9. doi: 10.1016/j.jtha.2023.09.008.
	37641391	0	Glise Sandblad K, Schulman S, Rosengren A, et al. Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-A nationwide register-based study. J Intern Med. 2023 Aug 28. doi: 10.1111/joim.13712.
	37640047	0	Schulman S. Recent Advances in Thrombosis and Hemostasis-Part IX. Semin Thromb Hemost. 2023 Aug 28. doi: 10.1055/s-0043-1772839.
	37439553	0	Gigante B, Levy JH, van Gorp E, et al. Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis. Eur Heart J. 2023 Jul 13:ehad388. doi: 10.1093/eurheartj/ehad388.
	37235671	0	Koulas I, Goldin M, Schulman S, et al. Antithrombotic therapy in the management of hospitalised patients with COVID-19. Br J Hosp Med (Lond). 2023 May 2;84(5):1-11. doi: 10.12968/hmed.2022.0519. Epub 2023 May 22.
	37015326	0	Gorman J, Candeloro M, Schulman S. Anticoagulant management and outcomes in non-traumatic intracranial hemorrhage complicated by venous thromboembolism: a retrospective chart review. Thromb Haemost. 2023 Apr 4. doi: 10.1055/a-2068-6464.
	36971601	0	Eikelboom R, Whitlock RP, Muzaffar R, et al. Direct oral anticoagulants versus vitamin K antagonists in the first 3 months after bioprosthetic valve replacement: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2023 Mar 27:ezad110. doi: 10.1093/ejcts/ezad110.
	36907381	0	Candeloro M, Valeriani E, Monreal M, et al. Clinical course and treatment of incidentally detected splanchnic vein thrombosis: an individual patient data meta-analysis. J Thromb Haemost. 2023 Mar 10:S1538-7836(23)00176-9. doi: 10.1016/j.jtha.2023.03.002.
	36710196	0	Caiano L, Kovacs MJ, Lazo-Langner A, et al. The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism. J Thromb Haemost. 2022 Dec 30:S1538-7836(22)19071-9. doi: 10.1016/j.jtha.2022.12.021.
	36434811	0	Hansen-Barkun C, Martel M, Douketis J, et al. Periprocedural Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant Undergoing a Digestive Endoscopy. Am J Gastroenterol. 2023 Jan 30. doi: 10.14309/ajg.0000000000002076.
	36294316	0	Kyriakoulis KG, Dimakakos E, Kyriakoulis IG, et al. Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. J Clin Med. 2022 Oct 11;11(20). pii: jcm11205997. doi: 10.3390/jcm11205997.
	36206783	0	Aibar J, Schulman S. Erratum: Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis. Semin Thromb Hemost. 2021 Sep;47(6):e1-e2. doi: 10.1055/s-0042-1757330. Epub 2022 Oct 7.
	36200348	0	Shaw JR, Li N, Nixon J, et al. Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure. J Thromb Haemost. 2022 Dec;20(12):2953-2963. doi: 10.1111/jth.15901. Epub 2022 Oct 18.
	35974661	0	Candeloro M, Di Nisio M, Potere N, et al. Frailty phenotype as a predictor of bleeding and mortality in ambulatory patients receiving direct oral anticoagulants. J Am Geriatr Soc. 2022 Aug 16. doi: 10.1111/jgs.18001.
	35918731	0	Holbrook AM, Vidug K, Yoo L, et al. Coordination of Oral Anticoagulant Care at Hospital Discharge (COACHeD): protocol for a pilot randomised controlled trial. Pilot Feasibility Stud. 2022 Aug 2;8(1):166. doi: 10.1186/s40814-022-01130-z.
	35906715	0	Spyropoulos AC, Connors JM, Douketis JD, et al. Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. J Thromb Haemost. 2022 Jul 7. doi: 10.1111/jth.15809.
	35877546	0	Abdulrehman J, Elbaz C, Aziz D, et al. Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis. Br J Haematol. 2022 Jul 25. doi: 10.1111/bjh.18331.
	35793687	0	Candeloro M, Schulman S. Arterial Thrombotic Events in Hospitalized COVID-19 Patients: A Short Review and Meta-Analysis. Semin Thromb Hemost. 2022 Jul 6. doi: 10.1055/s-0042-1749661.
	35790272	0	Dimakakos E, Gomatou G, Catalano M, et al. Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art. Anticancer Res. 2022 Jul;42(7):3261-3274. doi: 10.21873/anticanres.15815.
	35772400	0	Schulman S. Recent Advances in Thrombosis and Hemostasis-Part VIII. Semin Thromb Hemost. 2022 Jun;48(4):405-406. doi: 10.1055/s-0042-1748886. Epub 2022 Jun 30.
	35707621	0	Eagle GE, Schulman S. High Factor VIII Levels and Recurrent Thromboembolism in Patients with and without Inflammatory Bowel Disease: A Retrospective Comparative Study. TH Open. 2022 Jun 13;6(2):e147-e153. doi: 10.1055/a-1827-7464. eCollection 2022 Apr.
	35679460	0	Wells PS, Tritschler T, Khan F, et al. Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism. Blood Adv. 2022 Jun 9. pii: 485510. doi: 10.1182/bloodadvances.2022007027.
	35613465	0	Candeloro M, Valeriani E, Monreal M, et al. Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Blood Adv. 2022 May 25. pii: 485361. doi: 10.1182/bloodadvances.2022007961.
	35362102	0	Schulman S, Carlson V, Serrano PE, et al. Adherence to apixaban for extended thromboprophylaxis after major abdominal or pelvic surgery for cancer: A prospective cohort study. J Surg Oncol. 2022 Apr 1. doi: 10.1002/jso.26876.
	35224414	0	Candeloro M, Eikelboom JW, Chan N, et al. Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort. Res Pract Thromb Haemost. 2022 Feb 17;6(2):e12650. doi: 10.1002/rth2.12650. eCollection 2022 Feb.
	35015038	0	Goldenberg NA, Kittelson JM, Abshire TC, et al. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182.
	34852380	0	Makedonov I, Kahn SR, Abdulrehman J, et al. Prevention of the post thrombotic syndrome with anticoagulation: a narrative review. Thromb Haemost. 2021 Dec 1. doi: 10.1055/a-1711-1263.
	34807722	0	Le Gal G, Kovacs MJ, Bertoletti L, et al. Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study. Ann Intern Med. 2021 Nov 23. doi: 10.7326/M21-2981.
	34753191	0	Khan F, Rahman A, Tritschler T, et al. Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. Thromb Haemost. 2021 Nov 9. doi: 10.1055/a-1690-8728.
	34518263	0	Galanaud JP, Abdulrehman J, Lazo-Langner A, et al. MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial. BMJ Open. 2021 Sep 13;11(9):e049557. doi: 10.1136/bmjopen-2021-049557.
	34470058	0	Schulman S. Recent Advances in Thrombosis and Hemostasis-Part VII. Semin Thromb Hemost. 2021 Sep;47(6):621-622. doi: 10.1055/s-0041-1725945. Epub 2021 Sep 1.
	34453675	0	Goldhaber SZ, Ageno W, Casella IB, et al. Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. J Thromb Thrombolysis. 2021 Aug 28. pii: 10.1007/s11239-021-02463-x. doi: 10.1007/s11239-021-02463-x.
	34345092	0	Gabara C, Solarat B, Castro P, et al. Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients. Med Intensiva (Engl Ed). 2021 Jul 30. pii: S0210-5691(21)00178-9. doi: 10.1016/j.medin.2021.07.004.
	34318606	0	Candeloro M, van Es N, Cantor N, et al. Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021 Oct;19(10):2618-2628. doi: 10.1111/jth.15476. Epub 2021 Aug 8.
	34255420	0	Wik HS, Kahn SR, Eriksson H, et al. Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients. J Thromb Haemost. 2021 Oct;19(10):2495-2503. doi: 10.1111/jth.15449. Epub 2021 Jul 28.
	34108229	0	Kovacs MJ, Wells PS, Anderson DR, et al. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ. 2021 Jun 9;373:n1205. doi: 10.1136/bmj.n1205.
	33971682	0	Schellong S, Ageno W, Casella IB, et al. Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. Semin Thromb Hemost. 2021 May 10. doi: 10.1055/s-0041-1729169.
	33971678	0	Aibar J, Schulman S. Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis. Semin Thromb Hemost. 2021 Sep;47(6):709-723. doi: 10.1055/s-0041-1725057. Epub 2021 May 10.
	33792175	0	Khorsand N, Beyer-Westendorf J, Sarode R, et al. Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021 Apr;19(4):1112-1115. doi: 10.1111/jth.15222.
	33537540	0	Douketis JD, Syed S, Li N, et al. A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant. Res Pract Thromb Haemost. 2020 Dec 16;5(1):159-167. doi: 10.1002/rth2.12430. eCollection 2021 Jan.
	33368114	0	Kearon C, Carrier M, Gu CS, et al. Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial. Semin Thromb Hemost. 2020 Nov;46(8):977-985. doi: 10.1055/s-0040-1718891. Epub 2020 Dec 23.
	33368109	0	Schulman S. Recent Advances in Thrombosis and Hemostasis: Part VI. Semin Thromb Hemost. 2020 Nov;46(8):863-864. doi: 10.1055/s-0040-1715794. Epub 2020 Dec 23.
	33306241	0	Valeriani E, Di Nisio M, Riva N, et al. Clinical history of cancer-associated splanchnic vein thrombosis. J Thromb Haemost. 2021 Apr;19(4):983-991. doi: 10.1111/jth.15214. Epub 2021 Feb 24.
	33099284	0	Schulman S, Hu Y, Konstantinides S. Venous Thromboembolism in COVID-19. Thromb Haemost. 2020 Dec;120(12):1642-1653. doi: 10.1055/s-0040-1718532. Epub 2020 Oct 24.
	33007077	0	Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020 Oct 13;4(19):4693-4738. doi: 10.1182/bloodadvances.2020001830.
	32969288	0	Tafur AJ, Clark NP, Spyropoulos AC, et al. Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. J Am Heart Assoc. 2020 Oct 20;9(19):e017316. doi: 10.1161/JAHA.120.017316. Epub 2020 Sep 24.
	32968991	0	Aibar J, Schulman S. New-Onset Atrial Fibrillation in Sepsis: A Narrative Review. Semin Thromb Hemost. 2021 Feb;47(1):18-25. doi: 10.1055/s-0040-1714400. Epub 2020 Sep 23.
	32851572	0	Ageno W, Casella IB, Chee KH, et al. Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. J Thromb Thrombolysis. 2021 Apr;51(3):561-570. doi: 10.1007/s11239-020-02239-9.
	32756938	0	Shaw JR, Li N, Vanassche T, et al. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Adv. 2020 Aug 11;4(15):3520-3527. doi: 10.1182/bloodadvances.2020002335.
	32735828	0	Schulman S. Is venous thromboembolism a preventable cause of death? Lancet Haematol. 2020 Aug;7(8):e555-e556. doi: 10.1016/S2352-3026(20)30219-2.
	32619346	0	Di Nisio M, Valeriani E, Riva N, et al. Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. J Thromb Haemost. 2020 Jul;18(7):1562-1568. doi: 10.1111/jth.14836.
	32578414	0	Hwang HG, Kim YK, Kim MS, et al. Prophylaxis of Venous Thromboembolism in Patients with Infectious Disease. Tuberc Respir Dis (Seoul). 2020 Jul;83(3):255-256. doi: 10.4046/trd.2020.0029. Epub 2020 Apr 29.
	32526791	0	Schulman S, Konstantinides S, Hu Y, et al. Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. Thromb Haemost. 2020 Aug;120(8):1143-1146. doi: 10.1055/s-0040-1712913. Epub 2020 Jun 11.
	32496023	0	Tritschler T, Kraaijpoel N, Girard P, et al. Definition of pulmonary embolism-related death and classification of the cause of death in venous thromboembolism studies: Communication from the SSC of the ISTH. J Thromb Haemost. 2020 Jun;18(6):1495-1500. doi: 10.1111/jth.14769.
	32473596	0	Bikdeli B, Madhavan MV, Gupta A, et al. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost. 2020 Jul;120(7):1004-1024. doi: 10.1055/s-0040-1713152. Epub 2020 May 30.
	32392613	0	Schulman S. Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism. Semin Thromb Hemost. 2020 Oct;46(7):772-776. doi: 10.1055/s-0040-1710337. Epub 2020 May 11.
	32346486	0	Legault K, Blostein M, Carrier M, et al. A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. Pilot Feasibility Stud. 2020 Apr 25;6:52. doi: 10.1186/s40814-020-00594-1. eCollection 2020.
	32325043	0	Goldhaber SZ, Ageno W, Casella IB, et al. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE Study. Am J Med. 2020 Aug;133(8):936-945. doi: 10.1016/j.amjmed.2020.03.036. Epub 2020 Apr 20.
	32311448	0	Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17.
	32289164	0	Izcovich A, Criniti JM, Popoff F, et al. Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. Blood Adv. 2020 Apr 14;4(7):1539-1553. doi: 10.1182/bloodadvances.2020001513.
	32202042	0	Valeriani E, Porreca E, Weitz JI, et al. Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. J Thromb Haemost. 2020 Jul;18(7):1661-1671. doi: 10.1111/jth.14807. Epub 2020 Apr 16.
	32073218	0	Tritschler T, Kraaijpoel N, Langlois N, et al. Development of a standardized definition of pulmonary embolism-related death: A cross-sectional survey of international thrombosis experts. J Thromb Haemost. 2020 Jun;18(6):1415-1420. doi: 10.1111/jth.14775. Epub 2020 Mar 30.
	32040553	0	Khatib R, Ross S, Kennedy SA, et al. Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. Blood Adv. 2020 Feb 11;4(3):500-513. doi: 10.1182/bloodadvances.2019001223.
	32011635	0	Spyropoulos AC, Schulman S, Douketis JD. Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant-Reply. JAMA Intern Med. 2020 Feb 1;180(2):333-334. doi: 10.1001/jamainternmed.2019.5851.
	31774957	0	Kearon C, de Wit K, Parpia S, et al. Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability. N Engl J Med. 2019 Nov 28;381(22):2125-2134. doi: 10.1056/NEJMoa1909159.
	31675758	0	Schulman S. Recent Advances in Thrombosis and Hemostasis-Part V. Semin Thromb Hemost. 2019 Nov;45(8):757-759. doi: 10.1055/s-0039-1700490. Epub 2019 Nov 1.
	31624782	0	Murray S, McLintock C, Lazure P, et al. Needs and challenges among physicians and researchers in thrombosis and hemostasis: Results from an international study. Res Pract Thromb Haemost. 2019 Jun 28;3(4):626-638. doi: 10.1002/rth2.12237. eCollection 2019 Oct.
	31434018	0	Xu Y, Schulman S, Dowlatshahi D, et al. Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. Thromb Res. 2019 Oct;182:12-19. doi: 10.1016/j.thromres.2019.07.026. Epub 2019 Aug 2.
	31415251	0	Grottke O, Schulman S. Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors. Anesthesiology. 2019 Nov;131(5):1153-1165. doi: 10.1097/ALN.0000000000002910.
	31380891	0	Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019 Nov 1;179(11):1469-1478. doi: 10.1001/jamainternmed.2019.2431.
	31340984	0	Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019 Jul 24;366:l4363. doi: 10.1136/bmj.l4363.
	31033194	0	Kearon C, Parpia S, Spencer FA, et al. Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study. J Thromb Haemost. 2019 Jul;17(7):1144-1152. doi: 10.1111/jth.14458. Epub 2019 May 20.
	30822795	0	Schulman S. Recent Advances in Thrombosis and Hemostasis-Part IV. Semin Thromb Hemost. 2019 Mar;45(2):130-131. doi: 10.1055/s-0039-1678721. Epub 2019 Mar 1.
	30743281	0	Piran S, Schulman S. Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Narrative Review. Semin Thromb Hemost. 2019 Mar;45(2):150-156. doi: 10.1055/s-0039-1678720. Epub 2019 Feb 11.
	30658963	0	Piran S, Khatib R, Schulman S, et al. Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Adv. 2019 Jan 22;3(2):158-167. doi: 10.1182/bloodadvances.2018024133.
	30657628	0	Abdoellakhan RA, Beyer-Westendorf J, Schulman S, et al. Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding. J Thromb Haemost. 2019 Mar;17(3):499-506. doi: 10.1111/jth.14388. Epub 2019 Feb 13.
	30559261	0	Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019 Jan 31;133(5):425-435. doi: 10.1182/blood-2018-06-820746. Epub 2018 Dec 17.
	30487292	0	van der Wall SJ, van der Pol LM, Ende-Verhaar YM, et al. Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. Eur Respir Rev. 2018 Nov 28;27(150). pii: 27/150/180094. doi: 10.1183/16000617.0094-2018. Print 2018 Dec 31.
	30349887	0	Piran S, Traquair H, Chan N, et al. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. Res Pract Thromb Haemost. 2018 Aug 29;2(4):684-688. doi: 10.1002/rth2.12146. eCollection 2018 Oct.
	30261356	0	Dube C, Douketis JD, Moffat KA, et al. Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time. Thromb Res. 2018 Nov;171:62-67. doi: 10.1016/j.thromres.2018.09.051. Epub 2018 Sep 19.
	30201588	0	Schulman S. Splanchnic vein thrombosis: what are the long-term risks? Lancet Haematol. 2018 Oct;5(10):e431-e432. doi: 10.1016/S2352-3026(18)30137-6. Epub 2018 Sep 7.
	30108204	0	Senzolo M, Riva N, Dentali F, et al. Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. Clin Transl Gastroenterol. 2018 Aug 15;9(8):176. doi: 10.1038/s41424-018-0043-2.
	30046730	0	Shaw JR, Woodfine JD, Douketis J, et al. Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. Res Pract Thromb Haemost. 2018 Feb 16;2(2):282-290. doi: 10.1002/rth2.12076. eCollection 2018 Apr.
	30012319	0	Schulman S, Aisenberg J. Are NSAIDs Double Trouble? J Am Coll Cardiol. 2018 Jul 17;72(3):268-270. doi: 10.1016/j.jacc.2018.04.062. Epub 2018 Jul 9.
	29857347	0	Schulman S. Recent Advances in Thrombosis and Hemostasis - Part III. Semin Thromb Hemost. 2018 Jun;44(4):312-314. doi: 10.1055/s-0038-1654717. Epub 2018 Jun 1.
	29795666	0	Xu Y, Shoamanesh A, Schulman S, et al. Correction: Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts. PLoS One. 2018 May 24;13(5):e0198031. doi: 10.1371/journal.pone.0198031. eCollection 2018.
	29703478	0	Piran S, Schulman S. Management of recurrent venous thromboembolism in patients with cancer: A review. Thromb Res. 2018 Apr;164 Suppl 1:S172-S177. doi: 10.1016/j.thromres.2017.12.019.
	29564837	0	Schulman S, Gross PL, Ritchie B, et al. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Thromb Haemost. 2018 May;118(5):842-851. doi: 10.1055/s-0038-1636541. Epub 2018 Mar 21.
	29564687	0	Piran S, Gabriel C, Schulman S. Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study. J Thromb Thrombolysis. 2018 May;45(4):486-495. doi: 10.1007/s11239-018-1645-y.
	29490924	0	Kearon C, Parpia S, Spencer FA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018 May 10;131(19):2151-2160. doi: 10.1182/blood-2017-09-805689. Epub 2018 Feb 28.
	29397541	0	Piran S, Traquair H, Chan N, et al. Incidence and risk factors for acute kidney injury in patients with excessive anticoagulation on warfarin: a retrospective study. J Thromb Thrombolysis. 2018 May;45(4):557-561. doi: 10.1007/s11239-018-1626-1.
	29370183	0	Xu Y, Shoamanesh A, Schulman S, et al. Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts. PLoS One. 2018 Jan 25;13(1):e0191137. doi: 10.1371/journal.pone.0191137. eCollection 2018.
	29224638	0	Clark NP, Douketis JD, Hasselblad V, et al. Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. Am Heart J. 2018 Jan;195:108-114. doi: 10.1016/j.ahj.2017.09.015. Epub 2017 Sep 21.
	29212129	0	Douketis JD, Spyropoulos AC, Anderson JM, et al. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. Thromb Haemost. 2017 Dec;117(12):2415-2424. doi: 10.1160/TH17-08-0553. Epub 2017 Dec 6.
	29202209	0	Goldhaber SZ, Schulman S, Eriksson H, et al. Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Thromb Haemost. 2017 Nov;117(11):2045-2052. doi: 10.1160/TH17-03-0176. Epub 2017 Oct 4.
	29183221	0	Tarango C, Schulman S, Betensky M, et al. Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials. Expert Rev Hematol. 2018 Jan;11(1):37-44. doi: 10.1080/17474086.2018.1407241. Epub 2017 Dec 17.
	29170877	0	Piran S, Schulman S, Panju M, et al. Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers. J Thromb Thrombolysis. 2018 Jan;45(1):180-185. doi: 10.1007/s11239-017-1585-y.
	29136562	0	Chai-Adisaksopha C, Iorio A, Hillis C, et al. Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. Thromb Res. 2017 Dec;160:97-104. doi: 10.1016/j.thromres.2017.11.001. Epub 2017 Nov 11.
	29092088	0	Schulman S, Islam MS. Recent Advances in Thrombosis and Hemostasis-Part II. Semin Thromb Hemost. 2017 Nov;43(8):809-810. doi: 10.1055/s-0037-1605566. Epub 2017 Nov 1.
	29091811	0	Piran S, Bednar D, Drew B, et al. Optimal timing of starting thromboprophylaxis for patients with acute spinal cord injury: A survey of Canadian spine surgeons. Thromb Res. 2017 Dec;160:38-40. doi: 10.1016/j.thromres.2017.10.016. Epub 2017 Oct 26.
	28939565	0	Khan F, Rahman A, Carrier M, et al. Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. BMJ Open. 2017 Sep 21;7(9):16950. doi: 10.1136/bmjopen-2017-016950.
	28902373	0	Islam MS, Schulman S. Berzelius Symposium 93: International Conference on Thrombosis and Embolism. Semin Thromb Hemost. 2017 Nov;43(8):811-813. doi: 10.1055/s-0037-1605565. Epub 2017 Sep 8.
	28862285	0	Schulman S. Accumulating data on rivaroxaban for venous thromboembolism in clinical practice. Thromb Haemost. 2017 Oct 5;117(10):1840. doi: 10.1160/TH17-08-0573. Epub 2017 Sep 1.
	28835439	0	Majeed A, Agren A, Holmstrom M, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 2017 Oct 12;130(15):1706-1712. doi: 10.1182/blood-2017-05-782060. Epub 2017 Aug 23.
	28724590	0	Korompoki E, Filippidis FT, Nielsen PB, et al. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology. 2017 Aug 15;89(7):687-696. doi: 10.1212/WNL.0000000000004235. Epub 2017 Jul 19.
	28594049	0	Schulman S, Ageno W, Konstantinides SV. Venous thromboembolism: Past, present and future. Thromb Haemost. 2017 Jun 28;117(7):1219-1229. doi: 10.1160/TH16-10-0823. Epub 2017 Jun 8.
	28483766	0	Schulman S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood. 2017 Jun 22;129(25):3285-3293. doi: 10.1182/blood-2017-03-742304. Epub 2017 May 8.
	28424821	0	Schulman S, Singer D, Ageno W, et al. NOACs for treatment of venous thromboembolism in clinical practice. Thromb Haemost. 2017 Jun 28;117(7):1317-1325. doi: 10.1160/TH17-01-0065. Epub 2017 Apr 20.
	28364736	0	Schulman S. Bleeding Complications and Management on anticoagulant therapy. Semin Thromb Hemost. 2017 Nov;43(8):886-892. doi: 10.1055/s-0037-1602377. Epub 2017 Apr 1.
	28222322	0	Schulman S, Ritchie B, Nahirniak S, et al. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. Thromb Res. 2017 Apr;152:44-48. doi: 10.1016/j.thromres.2017.02.010. Epub 2017 Feb 16.
	28219635	0	Xu Y, Schulman S, Dowlatshahi D, et al. Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study. Chest. 2017 Jul;152(1):81-91. doi: 10.1016/j.chest.2017.02.009. Epub 2017 Feb 17.
	28210989	0	Feuring M, Schulman S, Eriksson H, et al. Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER((R)), RE-COVER II, and RE-MEDY. J Thromb Thrombolysis. 2017 May;43(4):484-489. doi: 10.1007/s11239-017-1479-z.
	28123190	0	Carlin S, Pickering J, Schulman S. Appropriateness of Apixaban Dosing to Prevent Stroke in Patients with Atrial Fibrillation: A Pilot Study. Can J Hosp Pharm. 2016 Nov-Dec;69(6):449-453. doi: 10.4212/cjhp.v69i6.1607. Epub 2016 Dec 23.
	28004062	0	Majeed A, Wallvik N, Eriksson J, et al. Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis. Thromb Haemost. 2017 Feb 28;117(3):491-499. doi: 10.1160/TH16-07-0498. Epub 2016 Dec 22.
	27853808	0	Ageno W, Casella IB, Han CK, et al. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost. 2017 Jan 26;117(2):415-421. doi: 10.1160/TH16-07-0566. Epub 2016 Nov 17.
	27829265	0	Schulman S, Islam MS. Recent Advances in Thrombosis and Hemostasis - Part I. Semin Thromb Hemost. 2016 Nov;42(8):805-807. doi: 10.1055/s-0036-1593544. Epub 2016 Nov 9.
	27807306	0	Goldhaber SZ, Eriksson H, Kakkar A, et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER(R), RE-COVER II, and RE-MEDY. Vasc Med. 2016 Dec;21(6):506-514. doi: 10.1177/1358863X16668588. Epub 2016 Nov 1.
	27766049	0	Piran S, Schulman S. Management of venous thromboembolism: an update. Thromb J. 2016 Oct 4;14(Suppl 1):23. doi: 10.1186/s12959-016-0107-z. eCollection 2016.
	27764881	0	Schulman S. Update on the Treatment of Venous Thromboembolism. Semin Thromb Hemost. 2016 Nov;42(8):891-898. doi: 10.1055/s-0036-1592305. Epub 2016 Oct 20.
	27721141	0	Piran S, Schulman S. Incidence and risk factors for venous thromboembolism in patients with acute spinal cord injury: A retrospective study. Thromb Res. 2016 Nov;147:97-101. doi: 10.1016/j.thromres.2016.09.030. Epub 2016 Oct 3.
	27471209	0	Klok FA, Hosel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016 Nov;48(5):1369-1376. doi: 10.1183/13993003.00280-2016. Epub 2016 Jul 28.
	27411591	0	Goldhaber SZ, Schellong S, Kakkar A, et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost. 2016 Sep 27;116(4):714-21. doi: 10.1160/TH16-04-0271. Epub 2016 Jul 14.
	27388221	0	Fatima S, Holbrook A, Schulman S, et al. Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation. Thromb Res. 2016 Sep;145:143-8. doi: 10.1016/j.thromres.2016.06.015. Epub 2016 Jun 16.
	27346552	0	Boonyawat K, Wang L, Lazo-Langner A, et al. The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial. Thromb Haemost. 2016 Aug 30;116(3):480-5. doi: 10.1160/TH16-04-0320. Epub 2016 Jun 23.
	27346176	0	Kittelson JM, Steg PG, Halperin JL, et al. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2016 Aug 30;116(3):544-53. doi: 10.1160/TH15-12-1000. Epub 2016 Jun 23.
	27264036	0	Riva N, Ageno W, Schulman S, et al. Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. Lancet Haematol. 2016 Jun;3(6):e267-75. doi: 10.1016/S2352-3026(16)30020-5. Epub 2016 May 11.
	27067968	0	Schulman S, Shrum J, Majeed A. Management of bleeding complications in patients with cancer on DOACs. Thromb Res. 2016 Apr;140 Suppl 1:S142-7. doi: 10.1016/S0049-3848(16)30113-X.
	26989185	0	Schulman S. Less menorrhagia for women with VTE. Blood. 2016 Mar 17;127(11):1378-9. doi: 10.1182/blood-2016-01-692053.
	26908016	0	Majeed A, Hwang HG, Eikelboom JW, et al. Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. Thromb Res. 2016 Apr;140:81-88. doi: 10.1016/j.thromres.2016.02.005. Epub 2016 Feb 22.
	26403199	0	Majeed A, Goldhaber SZ, Kakkar A, et al. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. Thromb Haemost. 2016 Jan;115(2):291-8. doi: 10.1160/TH15-04-0319. Epub 2015 Sep 24.
	26168152	0	Ageno W, Riva N, Schulman S, et al. Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry. JAMA Intern Med. 2015 Sep;175(9):1474-80. doi: 10.1001/jamainternmed.2015.3184.
	26095867	0	Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015 Aug 27;373(9):823-33. doi: 10.1056/NEJMoa1501035. Epub 2015 Jun 22.
	25966905	0	Schulman S, Carrier M, Lee AY, et al. Perioperative Management of Dabigatran: A Prospective Cohort Study. Circulation. 2015 Jul 21;132(3):167-73. doi: 10.1161/CIRCULATIONAHA.115.015688. Epub 2015 May 12.
	25868460	0	Schulman JM, Majeed A, Mattsson E, et al. Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves. J Thromb Thrombolysis. 2015 Nov;40(4):430-6. doi: 10.1007/s11239-015-1216-4.
	25739680	0	Schulman S, Goldhaber SZ, Kearon C, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015 Jul;114(1):150-7. doi: 10.1160/TH14-11-0977. Epub 2015 Mar 5.
	25717178	0	Bacchus F, Schulman S. Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):513-9. doi: 10.1161/ATVBAHA.114.303396. Epub 2014 Aug 14.
	25682084	0	Schulman S. Treatment of venous thromboembolism with new oral anticoagulants according to patient risk. Semin Thromb Hemost. 2015 Mar;41(2):160-5. doi: 10.1055/s-0035-1544157. Epub 2015 Feb 15.
	25560712	0	Kearon C, Spencer FA, O'Keeffe D, et al. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med. 2015 Jan 6;162(1):27-34. doi: 10.7326/M14-1275.
	25541032	0	Magnusson M, Berndtsson M, Fischler B, et al. Thrombin generation test in children and adolescents with chronic liver disease. Thromb Res. 2015 Feb;135(2):382-7. doi: 10.1016/j.thromres.2014.11.040. Epub 2014 Dec 13.
	25048833	0	Masotti L, Lorenzini G, Seravalle C, et al. Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. J Thromb Thrombolysis. 2015 May;39(4):427-33. doi: 10.1007/s11239-014-1112-3.